{"transactions":[{"id":1403089,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-09-18T17:16:21.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":1742858,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":200718},"source":{"system":"sec-edgar","filing":"0001104659-24-101030","document":"tm2424157-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1787092/000110465924101030/tm2424157-11_4seq1.xml","form_type":"4"}},{"id":1403088,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-18T17:16:21.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":3649263,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":420271},"source":{"system":"sec-edgar","filing":"0001104659-24-101030","document":"tm2424157-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1787092/000110465924101030/tm2424157-11_4seq1.xml","form_type":"4"}},{"id":1403087,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-18T17:16:21.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":1568480,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":180635},"source":{"system":"sec-edgar","filing":"0001104659-24-101030","document":"tm2424157-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1787092/000110465924101030/tm2424157-11_4seq1.xml","form_type":"4"}},{"id":1403086,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T17:16:21.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":200718,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":801624,"source":{"system":"sec-edgar","filing":"0001104659-24-101030","document":"tm2424157-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1787092/000110465924101030/tm2424157-11_4seq1.xml","form_type":"4"}},{"id":1403085,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T17:16:21.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":420271,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":600906,"source":{"system":"sec-edgar","filing":"0001104659-24-101030","document":"tm2424157-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1787092/000110465924101030/tm2424157-11_4seq1.xml","form_type":"4"}},{"id":1403084,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T17:16:21.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":180635,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."}],"balance_after":180635,"source":{"system":"sec-edgar","filing":"0001104659-24-101030","document":"tm2424157-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1787092/000110465924101030/tm2424157-11_4seq1.xml","form_type":"4"}},{"id":1450517,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-07-23T00:28:17.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":false,"shares":145089,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":145089},"source":{"system":"sec-edgar","filing":"0001415889-24-019908","document":"form4-07232024_120714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588924019908/form4-07232024_120714.xml","form_type":"4"}},{"id":1450516,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:28:17.000Z","date":"2024-07-22","kind":"other","planned":false,"acquired":true,"shares":49019,"price":10.2,"value":499993.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the conversion of outstanding simple agreement for future equity in the amount of $500,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price."}],"balance_after":194108,"source":{"system":"sec-edgar","filing":"0001415889-24-019908","document":"form4-07232024_120714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588924019908/form4-07232024_120714.xml","form_type":"4"}},{"id":1450515,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-07-23T00:28:17.000Z","date":"2024-07-22","kind":"exercise","planned":false,"acquired":true,"shares":145089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the \"IPO\"), the Series B Preferred Stock was\nconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date."}],"balance_after":145089,"source":{"system":"sec-edgar","filing":"0001415889-24-019908","document":"form4-07232024_120714.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588924019908/form4-07232024_120714.xml","form_type":"4"}},{"id":1552548,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2024-04-03T00:42:06.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":7142857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":366300},"source":{"system":"sec-edgar","filing":"0001415889-24-009885","document":"form4-04032024_120459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000141588924009885/form4-04032024_120459.xml","form_type":"4"}},{"id":1552547,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-04-03T00:42:06.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":false,"shares":3703704,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":189933},"source":{"system":"sec-edgar","filing":"0001415889-24-009885","document":"form4-04032024_120459.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000141588924009885/form4-04032024_120459.xml","form_type":"4"}},{"id":1552546,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T00:42:06.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":366300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date."}],"balance_after":556233,"source":{"system":"sec-edgar","filing":"0001415889-24-009885","document":"form4-04032024_120459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000141588924009885/form4-04032024_120459.xml","form_type":"4"}},{"id":1552545,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T00:42:06.000Z","date":"2024-04-02","kind":"exercise","planned":false,"acquired":true,"shares":189933,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."}],"balance_after":189933,"source":{"system":"sec-edgar","filing":"0001415889-24-009885","document":"form4-04032024_120459.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782303/000141588924009885/form4-04032024_120459.xml","form_type":"4"}},{"id":2108158,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-11-21T18:22:18.000Z","date":"2022-11-17","kind":"exercise","acquired":false,"shares":2190131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":888130},"source":{"system":"sec-edgar","filing":"0000950170-22-025513","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017022025513/ownership.xml","form_type":"4"}},{"id":2108157,"issuer":{"id":573,"kind":"organization","name":"Acrivon Therapeutics, Inc.","symbol":"ACRV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-21T18:22:18.000Z","date":"2022-11-17","kind":"exercise","acquired":true,"shares":888130,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date."}],"balance_after":888130,"source":{"system":"sec-edgar","filing":"0000950170-22-025513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017022025513/ownership.xml","form_type":"4"}},{"id":2618149,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-08-04T00:01:28.000Z","date":"2021-08-02","kind":"exercise","acquired":false,"shares":4831384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":897671},"source":{"system":"sec-edgar","filing":"0000899243-21-031393","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000089924321031393/doc4.xml","form_type":"4"}},{"id":2618148,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2021-08-04T00:01:28.000Z","date":"2021-08-02","kind":"exercise","acquired":true,"shares":897671,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into 0.1858 shares of the Issuer's Class A Common Stock. The Series B Preferred Stock had no expiration date."}],"balance_after":897671,"source":{"system":"sec-edgar","filing":"0000899243-21-031393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000089924321031393/doc4.xml","form_type":"4"}},{"id":2659183,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-22T17:14:44.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":10671482,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1152490},"source":{"system":"sec-edgar","filing":"0000899243-21-025303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025303/doc4.xml","form_type":"4"}},{"id":2659182,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2021-06-22T17:14:44.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":12436264,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1343081},"source":{"system":"sec-edgar","filing":"0000899243-21-025303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025303/doc4.xml","form_type":"4"}},{"id":2659181,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T17:14:44.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":1152490,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date."}],"balance_after":2495571,"source":{"system":"sec-edgar","filing":"0000899243-21-025303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025303/doc4.xml","form_type":"4"}},{"id":2659180,"issuer":{"id":11259,"kind":"organization","name":"Verve Therapeutics, Inc.","symbol":"VERV"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T17:14:44.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":1343081,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-2 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A-2 Preferred Stock had no expiration date."}],"balance_after":1343081,"source":{"system":"sec-edgar","filing":"0000899243-21-025303","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840574/000089924321025303/doc4.xml","form_type":"4"}},{"id":2768120,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-03-30T21:12:14.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":681812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":681812},"source":{"system":"sec-edgar","filing":"0000899243-21-013928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000089924321013928/doc4.xml","form_type":"4"}},{"id":2768119,"issuer":{"id":3965,"kind":"organization","name":"Edgewise Therapeutics, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-30T21:12:14.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":681812,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series C Preferred Stock had no expiration date."}],"balance_after":681812,"source":{"system":"sec-edgar","filing":"0000899243-21-013928","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710072/000089924321013928/doc4.xml","form_type":"4"}},{"id":2967393,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-11-24T22:36:39.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":451986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":451986},"source":{"system":"sec-edgar","filing":"0000899243-20-032050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000089924320032050/doc4.xml","form_type":"4"}},{"id":2967392,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-11-24T22:36:39.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":1273420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1273420},"source":{"system":"sec-edgar","filing":"0000899243-20-032050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000089924320032050/doc4.xml","form_type":"4"}},{"id":2967391,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-24T22:36:39.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":451986,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."}],"balance_after":1725406,"source":{"system":"sec-edgar","filing":"0000899243-20-032050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000089924320032050/doc4.xml","form_type":"4"}},{"id":2967390,"issuer":{"id":613,"kind":"organization","name":"Olema Pharmaceuticals, Inc.","symbol":"OLMA"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-24T22:36:39.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":1273420,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock. Each of the Series B Preferred Stock and Series C Preferred Stock had no expiration date."}],"balance_after":1273420,"source":{"system":"sec-edgar","filing":"0000899243-20-032050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750284/000089924320032050/doc4.xml","form_type":"4"}},{"id":3001605,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 convertible Preferred Stock","published_at":"2020-10-22T20:12:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":571143,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":571143},"source":{"system":"sec-edgar","filing":"0001209191-20-055562","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000120919120055562/doc4.xml","form_type":"4"}},{"id":3001604,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 convertible Preferred Stock","published_at":"2020-10-22T20:12:09.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1335048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1335048},"source":{"system":"sec-edgar","filing":"0001209191-20-055562","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000120919120055562/doc4.xml","form_type":"4"}},{"id":3001603,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-22T20:12:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":571143,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."}],"balance_after":1906191,"source":{"system":"sec-edgar","filing":"0001209191-20-055562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000120919120055562/doc4.xml","form_type":"4"}},{"id":3001602,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-22T20:12:09.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":1335048,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of series B-1 convertible preferred stock and series B-2 convertible preferred stock shall automatically convert into shares of\nCommon Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no\nexpiration date."}],"balance_after":1335048,"source":{"system":"sec-edgar","filing":"0001209191-20-055562","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000120919120055562/doc4.xml","form_type":"4"}},{"id":3020539,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series D Preferred Stock","published_at":"2020-09-29T20:48:42.000Z","date":"2020-09-29","kind":"exercise","acquired":false,"shares":760267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":760267},"source":{"system":"sec-edgar","filing":"0001209191-20-052351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1699382/000120919120052351/doc4.xml","form_type":"4"}},{"id":3020538,"issuer":{"id":7062,"kind":"organization","name":"PMV Pharmaceuticals, Inc.","symbol":"PMVP"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-09-29T20:48:42.000Z","date":"2020-09-29","kind":"exercise","acquired":true,"shares":760267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date."}],"balance_after":760267,"source":{"system":"sec-edgar","filing":"0001209191-20-052351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1699382/000120919120052351/doc4.xml","form_type":"4"}},{"id":3023915,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T22:56:45.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":5336179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1608785},"source":{"system":"sec-edgar","filing":"0000899243-20-026172","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026172/doc4.xml","form_type":"4"}},{"id":3023914,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T22:56:45.000Z","date":"2020-09-21","kind":"exercise","acquired":true,"shares":1608785,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":1608785,"source":{"system":"sec-edgar","filing":"0000899243-20-026172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026172/doc4.xml","form_type":"4"}},{"id":3045687,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-08-27T20:12:15.000Z","date":"2020-08-25","kind":"exercise","acquired":false,"shares":1529847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":959211},"source":{"system":"sec-edgar","filing":"0000899243-20-023500","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924320023500/doc4.xml","form_type":"4"}},{"id":3045686,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-27T20:12:15.000Z","date":"2020-08-25","kind":"exercise","acquired":true,"shares":959211,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1.5949-for-one basis. The Series C Preferred Stock had no expiration date."}],"balance_after":959211,"source":{"system":"sec-edgar","filing":"0000899243-20-023500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000089924320023500/doc4.xml","form_type":"4"}},{"id":3073231,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2020-07-31T00:08:17.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":784313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":784313},"source":{"system":"sec-edgar","filing":"0000899243-20-020811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000089924320020811/doc4.xml","form_type":"4"}},{"id":3073230,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-31T00:08:17.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":784313,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of Common Stock of the Issuer. The Series D Preferred Stock had no expiration date."}],"balance_after":784313,"source":{"system":"sec-edgar","filing":"0000899243-20-020811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000089924320020811/doc4.xml","form_type":"4"}},{"id":3099558,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-06-25T17:48:49.000Z","date":"2020-06-23","kind":"exercise","acquired":false,"shares":5359344,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1252913},"source":{"system":"sec-edgar","filing":"0001209191-20-038965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1538927/000120919120038965/doc4.xml","form_type":"4"}},{"id":3099557,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-25T17:48:49.000Z","date":"2020-06-23","kind":"purchase","acquired":true,"shares":1000000,"price":20,"value":20000000.0,"ownership":{"direct":true},"balance_after":2252913,"source":{"system":"sec-edgar","filing":"0001209191-20-038965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1538927/000120919120038965/doc4.xml","form_type":"4"}},{"id":3099556,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-25T17:48:49.000Z","date":"2020-06-23","kind":"exercise","acquired":true,"shares":1252913,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 23, 2020, the Series D Convertible Preferred Stock automatically converted into common stock on a 4.2775-for-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":1252913,"source":{"system":"sec-edgar","filing":"0001209191-20-038965","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1538927/000120919120038965/doc4.xml","form_type":"4"}},{"id":3105004,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-06-18T22:02:24.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":1788460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1012546},"source":{"system":"sec-edgar","filing":"0000899243-20-017119","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733294/000089924320017119/doc4.xml","form_type":"4"}},{"id":3105003,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T22:02:24.000Z","date":"2020-06-16","kind":"purchase","acquired":true,"shares":1100000,"price":19,"value":20900000.0,"ownership":{"direct":true},"balance_after":2112546,"source":{"system":"sec-edgar","filing":"0000899243-20-017119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733294/000089924320017119/doc4.xml","form_type":"4"}},{"id":3105002,"issuer":{"id":67174,"kind":"organization","name":"Generation Bio Co.","symbol":"GBIO"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-18T22:02:24.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":1012546,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":1012546,"source":{"system":"sec-edgar","filing":"0000899243-20-017119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733294/000089924320017119/doc4.xml","form_type":"4"}},{"id":3288896,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-02-05T23:06:04.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":1713541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":568185},"source":{"system":"sec-edgar","filing":"0000899243-20-003374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320003374/doc4.xml","form_type":"4"}},{"id":3288895,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":87410,"kind":"organization","name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","position":1,"cik":"0001787092","reported_name":"Wellington Biomedical Innovation Master Investors (Cayman) I L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-05T23:06:04.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":568185,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date."}],"balance_after":568185,"source":{"system":"sec-edgar","filing":"0000899243-20-003374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320003374/doc4.xml","form_type":"4"}}]}